trending Market Intelligence /marketintelligence/en/news-insights/trending/MvJrydhWGaJj-4qIwgeziA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

UPDATE: J&J Q3 earnings beat estimate; 2019 outlook raised

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

UPDATE: J&J Q3 earnings beat estimate; 2019 outlook raised

Johnson & Johnson, the world's biggest healthcare company by market value, said its third-quarter earnings increased by 1.5% and raised its guidance for 2019.

The New Brunswick, N.J.-based company booked third-quarter 2019 adjusted net earnings of $5.67 billion, or $2.12 per share, up from $5.59 billion, or $2.05 per share, in the year-ago period.

The S&P Global Market Intelligence consensus normalized EPS estimate for the quarter is $2.01.

Sales for the quarter totaled $20.73 billion, a 1.9% increase from $20.35 billion, a year earlier. Research and development expenses for the period were up 3.6% year over year to $2.60 billion from $2.51 billion.

On a GAAP basis, third-quarter net earnings amounted to $4.83 billion, or $1.81 per share, a year-over-year increase from $3.93 billion, or $1.44 per share.

The company slightly raised its full-year guidance for adjusted EPS to the range of $8.62 to $8.67, from the prior estimate of $8.53 to $8.63. The S&P Global Market Intelligence consensus normalized EPS estimate for 2019 is $8.61.

J&J also increased its estimated reported sales outlook and now expects $81.8 billion to $82.3 billion, compared to the previous range of $80.8 billion to $81.6 billion.

In addition, the company now forecasts adjusted operational EPS in the range of $8.84 to $8.89, up from the prior outlook of $8.73 to $8.83.

J&J makes a range of products from prescription drugs to baby powder.